At what enterprise value was STADA acquired in 2025?

During the acquisition of STADA by CAPVEST PARTNERS in 2025, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR.

What was the EV/EBITDA of STADA when it was acquired by CAPVEST PARTNERS?

The estimated EV/EBITDA multiple for STADA is in the range of 10x - 18x.

When was STADA acquired by CAPVEST PARTNERS?

STADA was acquired by CAPVEST PARTNERS in 2025.

What was the revenue of STADA at the time of the deal?

The revenue of STADA at the time of the deal is estimated to be in the range of 2.5b - 5b EUR.

What was the EBITDA of STADA during the acquisition?

STADA's EBITDA is estimated to be in the range of 450M - 900M EUR.

How is the data for the STADA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the STADA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.pehub.com/bain-capital-cinven-agree-deal-to-sell-majority-stake-in-stada-to-capvest/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaSTADA

09/2025

STADA acquired by CAPVEST PARTNERS

GERMANY Life Sciences / Pharma & Biotech / Generics / Labs EV 3b - 100b EUR

Context

CapVest Partners agreed to acquire a controlling majority stake in Stada from Bain Capital and Cinven. This deal serves as an alternative to a planned IPO in Frankfurt, which was shelved due to market volatility. Under the agreement, the previous owners (Bain and Cinven) will retain a significant minority stake to benefit from future upside. CapVest intends to support the management team's strategy of international expansion and further consolidation in the fragmented consumer health market. Canson Capital Partners is also expected to co-invest alongside CapVest.

It is worth noting that the fund Bain Capital / Cinven took control of Stada through an LBO in 2017.

STADA, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Bad Vilbel, Germany, Stada is a leading European pharmaceutical manufacturer. Historically a generics player, the company has successfully transformed into a diversified "three-pillar" business: Consumer Healthcare (brands like Nizoral, Grippostad, Snup), Generics, and Specialty Pharmaceuticals (including Biosimilars).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with STADA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2026	STADA	ORIFARM VMS	DENMARK	Nutrition & Dietary Supplements
04/2017	BAIN CAPITAL / CINVEN	STADA	GERMANY	Generics / Labs

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 2.5b - 5b EUR

EBITDA range: 450M - 900M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STADA by CAPVEST PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: stada

Acquirer: capvest partners